Non-mestatatic castrate-resistant prostate cancer

Non-metastatic Castrate-Resistant Prostate Cancer (CRPC)

Prostate cancer is the most commonly diagnosed male cancer in the United States. It is estimated that approximately 50,000 men die from prostate cancer every year. Approximately one in nine men will be diagnosed with prostate cancer in their lifetime. Non-metastatic castrate-resistant prostate cancer (CRPC) is an advanced form of prostate cancer typically characterized by the growth of tumors despite androgen deprivation therapy (ADT). This type of prostate cancer is a more aggressive form of the disease and can progress to metastatic disease.

There is currently no specific therapy approved for the treatment of non-metastatic CRPC, but several treatments are being researched. Some therapeutic options include immunotherapy, chemotherapy, targeted therapies, and hormonal therapy.


Immunotherapy works by stimulating the body's immune system to fight cancer cells. It is used to treat many types of cancer, and is being investigated as a treatment option for men with CRPC. In one study, immunotherapy has been shown to significantly improve progression-free survival in men with non-metastatic CRPC.


Chemotherapy is a cancer treatment that uses drugs to kill or stop the growth of cancer cells. Several chemotherapy drugs have been studied as treatment options in CRPC, but the results have been inconclusive. A combination of the chemotherapy drugs cabazitaxel and abiraterone has been shown to be effective for some men, but the overall results are still uncertain.

Targeted Therapy

Targeted therapies are drugs that target specific molecules or pathways in cancer cells. They work by blocking the growth or spread of cancer cells. Some targeted therapies that have been used to treat CRPC include sipuleucel-T and abiraterone. Sipuleucel-T works by targeting certain cells of the immune system to help the body destroy cancer cells. Abiraterone works to block the production of male hormones in the body that can fuel the growth of CRPC.

Hormonal Therapy

Hormonal therapy is the use of drugs to block or decrease the production of hormones that can fuel the growth of prostate cancer. Hormonal therapy has been used to treat CRPC, but the side-effects can be severe. Common side-effects of hormonal therapy include hot flashes, exhaustion, weight gain, and decreased sex drive.


Non-metastatic castrate-resistant prostate cancer is a more aggressive form of prostate cancer and can be difficult to treat. Several treatment options are being investigated, including immunotherapy, chemotherapy, targeted therapy, and hormonal therapy. Each of these treatments have pros and cons and may not be suitable for every patient, so it is important to discuss these options with a doctor.